Dr David A. Williams (Boston Children’s Hospital, USA) said that the 3 patients, who are now 18, 10, and 9 months post-infusion, are all producing significantly increased amounts of the healthy form of haemoglobin and have so far shown no therapy-related adverse effects beyond those expected with autologous haematopoietic stem cell transplantation [1].
Dr Williams and colleagues hypothesised that knocking down BCL11A with RNA interference would re-induce foetal gamma-globulin expression. They genetically engineered a virus to deliver a gene that blocks the BCL11A protein in red blood cells using microRNA to simultaneously increase foetal haemoglobin and decrease sickle haemoglobin. Preclinical work in mice has shown that erythroid-specific expression of microRNA-adapted short hairpin RNAs (shRNAmiR) targeting BCL11A effectively induced foetal haemoglobin in human erythroid cells derived from transduced haematopoietic stem cells, mitigating the haematologic effects of sickle cell disease while avoiding negative effects in the stem cells and B lymphocytes.
Post-treatment follow-up shows that all 3 adult patients now have normal or near-normal haemoglobin levels and are producing foetal haemoglobin in quantities that should be sufficient to prevent sickling of red blood cells. One patient continues to receive planned blood transfusions due to extensive pre-existing blood vessel damage in the brain to reduce any risk of stroke, but the patient now needs fewer transfusions than before receiving the investigational gene therapy.
Two adolescents aged 16 and 12 years old have also received the gene therapy, at 5 months and 1 month post-treatment. Similarly, these patients are benefitting from the gene therapy. For all patients, the hope is that increasing foetal haemoglobin levels enough to prevent sickling will decrease their pain, as well as their long-term risk for sickle cell disease-related complications such as organ damage, strokes, and lung disease. Long-term follow up is needed.
1. Esrik EB, et al. LBA-5, ASH 2019, 7-10 December, Orlando, USA.
Posted on
Previous Article
« BCMA-targeted CAR T therapy yields 100% response in relapsed/refractory MM Next Article
CAR T-cell therapy successful in older non-Hodgkin’s lymphoma patients »
« BCMA-targeted CAR T therapy yields 100% response in relapsed/refractory MM Next Article
CAR T-cell therapy successful in older non-Hodgkin’s lymphoma patients »
Table of Contents: ASH 2019
Featured articles
Late-Breaking Abstracts
Likely new standard of care: Blinatumomab for children with relapsed B-ALL
Pivotal phase 3 trial in cold agglutinin disease: sutimlimab can stop haemolysis
Oral azacitidine improves overall survival in patients with AML in remission
BCL11A as a novel target in gene therapy for sickle cell disease
Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM
Long-term data of ropeginterferon alpha-2b in polycythaemia vera
Anti-CD70 is safe with hypomethylating agents in AML
MRD assessment to guide pre-emptive treatment decisions
Luspatercept effective for myelofibrosis-associated anaemia
Arsenic, ATRA, and ascorbic acid in acute promyelocytic leukaemia maintenance
Updated results ECOG-ACRIN E2906: decitabine maintenance after alloSCT
Sickle Cell Disease
Arginine supplements help against sickle cell disease pain
Abatacept prevents graft-versus-host disease in sickle cell patients after alloSCT
Plenary Scientific Session
HOVON-96: Better outcomes with cyclophosphamide after transplantation
Erythroferrone and skeletal changes associated with thalassaemia
Experimental model for limitations of haematopoietic stem cells propagation
Mosunetuzumab: complete remissions in non-Hodgkin lymphoma
Inclusive Medicine
Socioeconomic disparities and survival in paediatric AML
Oral selinexor/pomalidomide/dexamethasone shows activity in heavily pre-treated multiple myeloma
CAR T-cell therapy successful in older non-Hodgkin’s lymphoma patients
Mild renal impairment in African Americans does not affect OS in AML
ALCYONE: New overall survival results for myeloma
Venous Thromboembolism
Rivaroxaban is safe and effective for paediatric venous thromboembolism
Aspirin plus DOAC is not better than a DOAC alone
20-Year follow-up of imatinib in chronic myeloid leukaemia after failure with interferon
CAR T and Beyond
BCMA-targeted CAR T therapy yields 100% response in relapsed/refractory MM
Anti-BCMA/anti-CD38 in refractory multiple myeloma
Related Articles
August 5, 2021
Immune therapy of multiple myeloma
October 20, 2021
Some young people who undergo HCT retain ability to conceive
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy